Rectal Bleeding: Drugs That Cause It, Drugs That Treat It, and When to Act

The direct answer

Rectal bleeding has many possible sources, most of them benign (hemorrhoids, anal fissures) and some serious (diverticular disease, inflammatory bowel disease, colorectal polyps or cancer). Medications rarely cause rectal bleeding on their own; more often they convert a minor, self-limited bleed from an existing lesion into one that is heavier or slower to stop. NSAIDs and aspirin injure the GI lining directly. Anticoagulants, antiplatelet drugs, and SSRIs do not create lesions but impair the body's ability to seal one off once it starts. That distinction, cause versus amplifier, determines whether the right response is to stop a drug, add a protective medication, or simply get the underlying source diagnosed and treated. Guideline bodies including the American College of Gastroenterology (ACG) and the U.S. Preventive Services Task Force (USPSTF) recommend colonoscopy for any new rectal bleeding in adults aged 45 or older, regardless of suspected cause, before assuming it is benign.

Is this an emergency right now?

Answer this before reading further if bleeding is active.

Go to an emergency department immediately if you have:

• A fast heart rate, dizziness, fainting, or a blood pressure drop on standing
• Blood filling the toilet bowl, passing clots, or bleeding that won't stop
• Rectal bleeding along with severe abdominal pain, vomiting blood, or black tarry stool (possible upper GI source)

Seek care within 24 hours for:

• Maroon-colored blood mixed through stool (suggests a colonic source such as diverticular bleeding or angiodysplasia)
• New bleeding in anyone aged 45 or older
• Bleeding with unintentional weight loss, a change in bowel habits, or a family history of colorectal cancer
• Bleeding in anyone on an anticoagulant, antiplatelet drug, or NSAID, even if it seems minor, so the medication's role can be assessed

Reasonable to monitor and discuss at a routine visit:

• Small amounts of bright red blood on tissue only, with known hemorrhoids or a fissure, in someone under 45 with no other symptoms and no bleeding-risk medications on board

This is a general framework, not a substitute for individual assessment. Any bleeding that persists beyond a few days, recurs, or causes uncertainty should be evaluated by a clinician.

What usually causes rectal bleeding, apart from medication

Hemorrhoids. Engorged veins in the anal canal that bleed with straining or hard stool. Widely reported as the single most common cause of outpatient rectal bleeding. Blood is typically bright red, coats the stool or tissue, and is not mixed into it.

Anal fissures. A small tear in the anal lining, usually causing sharp pain during and after a bowel movement along with bright red blood. Fissures are common and usually heal with fiber, stool softeners, and topical treatment.

Diverticular disease. Small outpouchings in the colon wall, most common in older adults, that can bleed suddenly and painlessly, sometimes heavily. This is a frequent cause of hospitalization for lower GI bleeding, and anticoagulant or antiplatelet use raises both the frequency and volume of these bleeds.

Inflammatory bowel disease (IBD). Ulcerative colitis and Crohn's disease affect several million adults in the United States; the CDC has published national prevalence estimates for IBD. Prevalence of Inflammatory Bowel Disease Among Adults Aged >= 18 Years, United States, 2015 (CDC MMWR) Bloody diarrhea is a hallmark of active ulcerative colitis. NSAID use is a recognized trigger for IBD flares and can provoke bleeding in previously quiet disease; this association is well described in the gastroenterology literature, though the exact flare rate attributable to NSAIDs varies across studies and should be confirmed against a current primary source before quoting a specific figure.

Polyps and colorectal cancer. Rectal bleeding is a common presenting symptom of colorectal cancer, which is why age-based referral thresholds exist. Most people with rectal bleeding do not have cancer, but the only way to rule it out reliably in someone at average risk age 45 or older is direct visualization (colonoscopy or, in some triage pathways, flexible sigmoidoscopy).

Which medications make rectal bleeding more likely, or harder to stop

NSAIDs and aspirin: they damage the lining

Ibuprofen, naproxen, diclofenac, and other non-selective NSAIDs block the COX-1 enzyme responsible for protective prostaglandins throughout the GI tract, including the lower colon and rectum. This mechanism is well established, and non-selective NSAID use is consistently associated with several-fold higher rates of serious GI bleeding compared with non-use in the epidemiologic literature; the precise multiplier varies by study population and dose, and a specific number should be checked against a current systematic review before being stated as fixed.

Low-dose aspirin, even enteric-coated, irreversibly disables platelet COX-1 for the roughly 7-to-10-day lifespan of each platelet, meaning its bleeding effect outlasts the dose. The randomized ASPREE trial in healthy older adults found aspirin increased major bleeding events compared with placebo. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly (NEJM, ASPREE) That trial was conducted in people without an established indication for aspirin; it does not directly answer the risk-benefit question for someone taking aspirin after a cardiac stent, which is a different population.

Anticoagulants: they don't damage tissue, they stop the seal

Warfarin and the direct oral anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran, edoxaban) do not cause GI lesions. They prevent the clotting cascade from sealing off bleeding once it starts, so an ordinary hemorrhoid or diverticulum bleeds longer and more heavily than it otherwise would. Randomized trial data comparing individual DOACs on GI bleeding specifically (for example ROCKET-AF for rivaroxaban and ARISTOTLE for apixaban) exist in the cardiology literature, but the exact comparative GI bleeding rates reported in secondary summaries are easy to misquote from memory; anyone relying on a specific percentage difference between DOACs for a clinical decision should pull the original trial publication rather than a derived figure.

Antiplatelet agents

Clopidogrel, ticagrelor, and prasugrel impair platelet aggregation. Dual antiplatelet therapy (aspirin plus a second antiplatelet drug), standard after a coronary stent or acute coronary syndrome, carries a higher GI bleeding rate than aspirin alone in trial data, which is why PPI co-prescription is now common practice in patients with prior GI bleeding who are placed on dual antiplatelet therapy.

SSRIs and SNRIs

Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors deplete the platelet's serotonin stores, which platelets need to aggregate normally. This gives SSRIs a modest, independent association with GI bleeding, and the risk appears to compound meaningfully when an SSRI is combined with an NSAID. Sertraline and paroxetine have the strongest serotonin reuptake affinity among commonly prescribed SSRIs, which is the proposed mechanistic reason they carry a comparatively larger platelet effect, though this has not been shown to translate into a clean dose-response bleeding hierarchy in clinical outcome data.

Systemic corticosteroids

Oral or IV corticosteroids (prednisone, methylprednisolone, dexamethasone) thin GI mucosa and reduce mucosal cell turnover. Their bleeding risk alone is modest but rises substantially when combined with an NSAID, a combination that occurs commonly in patients treated for a flare of both joint and bowel or lung disease.

Medications that mimic bleeding without causing it

Iron supplements (ferrous sulfate, ferrous gluconate) turn stool black and can be mistaken for melena (true upper GI bleeding). Bismuth subsalicylate has the same effect. Neither causes bleeding, but both can confuse an evaluation if the clinician isn't told about them.

Medications used to treat the causes of rectal bleeding

These treat the underlying lesion, not the bleeding symptom in isolation.

Mesalamine (5-ASA) for ulcerative colitis and proctitis. Rectal mesalamine (suppositories or enemas) delivers anti-inflammatory drug directly to inflamed rectal and distal colonic mucosa and is generally regarded, in ACG and other GI society guidance, as first-line therapy for mild-to-moderate distal ulcerative colitis and proctitis, often preferred over rectal corticosteroids for inducing remission. The exact wording of any specific guideline statement should be pulled from the current published guideline rather than quoted from memory, since guideline text changes between revisions.

Topical corticosteroids. Hydrocortisone suppositories or foam reduce inflammation in proctitis and hemorrhoidal disease and are generally used short-term (a few weeks) to limit systemic steroid exposure. Budesonide formulations with low systemic bioavailability are an alternative for colonic and rectal inflammation where minimizing systemic steroid effect matters.

Topical nitrates and calcium-channel blockers for anal fissures. Glyceryl trinitrate (GTN) ointment and diltiazem gel both relax the internal anal sphincter, improve local blood flow, and are recommended by colorectal surgical societies as first-line pharmacologic treatment for chronic anal fissures before surgery is considered. Diltiazem is generally better tolerated, with fewer headaches than GTN.

PPIs as gastroprotection, not treatment. When an NSAID, aspirin, or dual antiplatelet regimen cannot safely be stopped, adding a proton-pump inhibitor (omeprazole, esomeprazole, or pantoprazole) reduces the risk of GI mucosal injury. A Cochrane systematic review of PPI co-therapy with NSAIDs found it reduced endoscopically detected ulcers compared with NSAID use alone. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane) A PPI protects the upper GI tract; it does not specifically prevent lower GI (rectal) bleeding, and this distinction matters when the bleeding source is confirmed to be in the rectum or distal colon rather than the stomach or duodenum.

Sucralfate enemas for radiation proctitis. In people who develop chronic rectal bleeding after pelvic radiotherapy, sucralfate enemas coat the irradiated mucosa and have shown benefit in small trials. This is a narrower, specific indication and not a general treatment for rectal bleeding of other causes.

Tranexamic acid, used cautiously. This antifibrinolytic drug is sometimes used in acute GI hemorrhage, including some post-procedural bleeding. The large HALT-IT trial found that tranexamic acid did not reduce GI-bleeding-related death at 5 days compared with placebo in a broad population with GI bleeding, which argues against treating it as a general fix for GI bleeding outside specific, narrower situations where a clinician judges it appropriate.

Should you stop your blood thinner or NSAID?

This is not a decision to make alone. Stopping an anticoagulant carries its own risk (stroke, clot), and that risk has to be weighed against ongoing bleeding. The general framework used in practice, reflected in ACG and cardiology society guidance, has three steps:

1. Assess how serious the bleeding actually is. Spotting from a known hemorrhoid is not the same as heavy, ongoing, or hemodynamically significant bleeding.
2. Find and treat the source, often via colonoscopy with clip or thermal therapy if a discrete bleeding point is found, rather than simply stopping the drug indefinitely.
3. Resume anticoagulation when appropriate, usually within one to two weeks after the bleeding source has been controlled, because prolonged discontinuation raises the risk of stroke or clot, which for many patients is more dangerous than a modest increase in rebleeding risk. The magnitude of that tradeoff varies by the reason someone is on anticoagulation (atrial fibrillation, mechanical valve, prior clot) and should be individualized by the prescribing physician, not inferred from a general statistic.

Do not stop an anticoagulant, antiplatelet drug, or any prescribed medication on your own because of rectal bleeding. Contact the prescribing clinician, and go to emergency care if bleeding is heavy or you feel lightheaded.

How rectal bleeding gets worked up

A clinician will ask about stool color and consistency, timing relative to bowel movements, pain, weight loss, and a full medication list, particularly anticoagulants, antiplatelet drugs, and NSAIDs. Digital rectal exam and, often, bedside anoscopy can identify hemorrhoids or a fissure immediately.

Blood work typically includes a complete blood count (to check for anemia from chronic or ongoing loss), iron studies, and coagulation testing if anticoagulant use is a factor.

Colonoscopy is the standard diagnostic tool for lower GI bleeding and is generally preferred over CT colonography or flexible sigmoidoscopy when a source in the left colon or rectum has not been excluded, per ACG guidance on acute lower GI bleeding. Reported rates of finding a definitive source at colonoscopy for acute lower GI bleeding vary across studies (commonly cited in a broad range around 40 to 75 percent); this range should be checked against the current ACG guideline document before it is used as a precise, quotable figure. CT angiography is preferred instead of colonoscopy in patients who are too unstable for bowel preparation, or when a prior colonoscopy was negative but bleeding continues.

What is established, what is plausible, and what isn't settled

Established: NSAIDs and aspirin damage the GI mucosa and raise bleeding risk through a well-documented COX-1 mechanism. Anticoagulants and antiplatelet drugs increase the volume and duration of bleeding from existing lesions rather than creating new ones. Age 45 and older with new rectal bleeding warrants colonoscopy evaluation under current U.S. screening guidance. Hemorrhoids and anal fissures are the most common benign causes of rectal bleeding.

Plausible but not fully settled: The exact magnitude of added risk from combining an SSRI with an NSAID, or an NSAID with a corticosteroid, is described consistently in the literature as compounding rather than simply additive, but the precise multipliers reported across different studies vary and shouldn't be treated as a fixed universal number. Whether tranexamic acid has meaningful benefit outside specific post-procedural settings remains uncertain given the null result of the largest trial to date in undifferentiated GI bleeding.

Not established from the material available here: Specific comparative GI bleeding rates between individual DOACs, precise percentage risk figures tied to particular studies cited in earlier drafts of this article, and exact wording of specific guideline statements. These require direct verification against the primary trial or guideline document before being restated as fact, and none of them should be treated as confirmed until that check is done.

A decision framework: what your medication has to do with your bleeding

Use this to separate "is my drug the problem" from "how urgent is this," which are different questions with different next steps.

The point of this table is not to replace an exam. It is to keep a reader from making the two most common mistakes: stopping a necessary blood thinner out of fear, or dismissing new bleeding after age 45 as "probably just hemorrhoids" without confirmation.